The US$16.6 billion acquisition of the "world's smallest artificial heart" manufacturer was the largest M&A of the year in the medical device field

Johnson & Johnson announced that it will spend about $16.
6 billion to acquire artificial heart maker Abiomed to consolidate its cardiovascular device business
.
Under the agreement, Johnson & Johnson will make an offer to acquire all outstanding shares of Abiomed with an advance payment of $380 per share in cash, equivalent to approximately $16.
6 billion.

Johnson & Johnson will also grant Abiomed shareholders an Expected Value Right (CVR) to receive up to $35 additional per
share if additional commercial and clinical trial milestones are subsequently achieved.

It is worth mentioning that this acquisition is the first major acquisition of Johnson & Johnson since it announced the divestiture of its consumer health business last year, and it is also one of
the largest acquisitions in Johnson & Johnson's history.
At the same time, this is also the largest merger and acquisition in the field of medical devices in
2022 so far.

Founded in 1981, Abiomed is the world's leading cardiovascular medical technology giant with a first-of-its-kind portfolio
for the treatment of coronary artery disease and heart failure.
Abiomed's flagship product is the Impella Heart Pump, also known as "the world's smallest artificial heart", which can effectively deliver blood and oxygen throughout the body by temporarily assisting the heart's pumping function, allowing the heart to rest and recover
.

Currently, Abiomed has a line of Impella heart pumps, including Impella 2.
5, Impella 5.
0, Impella 5.
5, and Impella Different models such as RP and Impella CP are used in patients
with severe coronary artery disease requiring high-risk PCI (percutaneous coronary intervention), AMI (acute myocardial infarction) cardiogenic shock, or right heart failure.

Image source: Abiomed official website